# Muna Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/muna-therapeutics

- Industry: Biotechnology
- Headquarters: Copenhagen, Denmark
- Website: www.munatherapeutics.com
- Total disclosed funding: $72M
- Latest round: Series A (Jul 9, 2021)
- Investors on record: 8

## About

Based in Copenhagen, Denmark, and founded in 2020 by co-founders Bart De Strooper and Simon Glerup, Muna Therapeutics operates as a biopharmaceutical company. The company was founded by Professor Simon Glerup. In July 2021, Muna Therapeutics raised DKK 450 million in Series A funding co-led by DROIA Ventures, Life Sciences Partners, Novo Holdings and Sofinnova Partners, with participation from Polaris Partners, Sanofi Ventures, V-Bio Ventures, and VIB.

Muna Therapeutics is a private biopharmaceutical company that discovers and develops therapies for neurodegenerative diseases including Alzheimer's, Frontotemporal Dementia, and Parkinson's. These disorders impact memory, movement, language, behavior, and personality resulting in the disability and death of millions of patients globally. The company focuses on science that identifies new medicines to preserve cognition and other brain functions and enhance resilience to neurodegenerative diseases.

## Funding rounds

- Series A, Jul 9, 2021, $72M — Sofinnova Partners, Polaris Partners, EQT Life Sciences, Novo Holdings, Sanofi Ventures, VIB, V-Bio Ventures, Droia Ventures

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A
- Novo Holdings — Series A
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series A
- VIB — Series A
- V-Bio Ventures (https://capitalatlas.ai/funds/v-bio-ventures) — Series A
- Droia Ventures (https://capitalatlas.ai/funds/droia-ventures) — Series A